Presentation on the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended September 30, 2026 is attached.

Ref: AHCL/2026-27/C051 November 05, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 Scrip Code – 544350 Symbol : AGARWALEYE Dear Sir / Madam, Sub: Analyst / Earnings Conference Call - Presentation Ref: Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to the captioned subject, reference and our letter dated October 23, 2026, we enclose herewith, the Presentation on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026, to be made at the Analyst / Earnings conference call scheduled today, i.e. November 05, 2026, at 06:30 P.M. IST. The details of the aforesaid call and the presentation are also available on the website of the Company at: https://dragarwals.co.in/#financials/analyst-earnings-call. We request you to kindly take the above on record. For Dr. Agarwal’s Health Care Limited Thanikainathan Arumugam Company Secretary and Compliance Officer Encl.: as above. DR. AGARWAL’S Indirapuram Najafgarh HEALTH CARE LIMITED Sarjapura Kazakoottam Indiranagar H1’FY27 Investor Presentation November 2026 Nikol This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. No representation, warranty, guarantee or undertaking, express or implied, is or will be made or any assurance given as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of any information, estimates, projections or opinions contained herein. You must make your own assessment of the relevance, accuracy and adequacy of the information contained in this presentation and must make such independent investigation as you may consider necessary or appropriate. Certain analysis undertaken and represented in this document may constitute an estimate from the Company and may differ from the actual underlying results. R The information provided in this presentation by the Company is for information purposes only. This presentation or any information herein shall not be used, reproduced, copied or duplicated in any form or by any means, or re-circulated, redistributed, passed on, published in any media, website or otherwise disseminated, to any other person, in any form or manner. This presentation does not constitute an offer or invitation or inducement to purchase or sell or subscribe to, any securities of the Company. This M presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document to purchase or sell securities under the Companies Act, 2013 and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 or any other applicable law, as amended from time to time. A The statements contained in this presentation speak only as at the date as of which they are made, and the Company expressly disclaims any obligation or undertaking to supplement, amend or disseminate any updates or revisions to any statements contained herein to reflect any change in events, conditions or circumstances on which any such statements are based. Neither the Company nor any of its affiliates, its board of directors, its management, advisers or representatives shall have any responsibility or liability whatsoever (in negligence or otherwise) for any loss (direct or indirect) howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such revision or changes. D Certain statements made in this presentation may be “forward looking statements” for purposes of laws and regulations of India and other than India. These statements include descriptions regarding the intent, belief or current expectations of the Company or its directors and officers with respect to the results of operations and financial condition, general business plans and strategy, the industry in which the Company operates and the general, business, competitive and regulatory environment of the Company. These statements can be recognized by the use of words such as “expects,” “plans,” “will,” “estimates,” “projects,” or other words of similar meaning. Such forward- looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in such forward-looking statements as a result of various factors and assumptions, including future changes or developments in the Company’s business, its competitive environment, information technology and political, economic, legal, regulatory, environmental and social conditions in India, which the Company believes to be reasonable in light of its operating experience in recent years. The Company does not undertake to revise any forward-looking statement that may be made from time to time by or on behalf of the Company. The distribution of this presentation in certain jurisdictions may be restricted by law and persons in whose possession this presentation comes should inform themselves about, and observe, any such restrictions. Eyes On The Future AGENDA PERFORMANCE SNAPSHOT BUSINESS UPDATES FINANCIAL PERFORMANCE UPDATE ABOUT THE COMPANY OVERVIEW OF EYE CARE INDUSTRY PERFORMANCE SNAPSHOT We are INDIA’S Financial Overview LARGEST Eye Care Services Revenue from Operations IndAS EBITDA(1) Profit After Tax ₹655 Cr. ₹186 Cr. ₹57 Cr. Chain F 2 Q 31.4% YoY Growth 28.8% YoY Growth 55.8% YoY Growth 7 ₹1,269 Cr. ₹362 Cr. ₹112 Cr. H 28.7% YoY Growth 27.0% YoY Growth 50.1% YoY Growth Operational Overview 324 1,844K+ 1,110+ Trusted Brand 7 Eye Care Facilities(2) Patients Served Doctors H 39 186K+ 2,400+ Facility Additions Surgeries Performed Paramedics Source: Crisil Intelligence Note: As of Sep 30, 2026 (1) EBITDA calculated as Profit Before Tax + Depreciation, Amortisation and Impairment Expense + Finance Costs and Includes Other Income 5 (2) As of Sep 30, 2026; Includes closure of three primary facilities in Janipur (Jammu) and Zirakpur (Punjab) in Q1’FY27, and Peer Muchalla (Punjab) in Q2’FY27 Our Geographic Footprint 89.6% 10.4% North Jammu & 5 Revenue from Operations Revenue from Operations 36 Kashmir Chandigarh Punjab 7 4 Haryana 8 Delhi Uttar Pradesh Rajasthan Ghana Uganda 1 Kenya Gujarat 11 Madhya Pradesh 3 West Bengal 1 Rwanda 11 Tanzania West 1 East 4 40 Orissa Maharashtra 14 Mozambique Telangana 2 32 Zambia Andhra Pradesh Mauritius 40 4 Karnataka 3 305 Puducherry Andaman & 19 Madagascar 1 Nicobar Islands 88 1 10 1 Kerala South Tamil Nadu 14 states 9 & 5 UTs Countries With a diversified presence across 172 cities, India remains our core focus market Clinical Excellence | Technology-Enabled Precision Care Specialized Surgical Procedures (H1’FY27) Advanced Ophthalmic Equipment 3,284 Femto Cataracts (25.5% YoY Growth) 3,785 Lenticular Procedure (41.9% YoY Growth) Alcon Unity VCS Clarus 700 Stellaris PC Elite 7,849 Vitrectomy Machine Fundus Camera with FFA Vitrectomy Machine Chennai Main Hospital, Chennai Borivali, Maharashtra Dwarka, Delhi Retinal Surgeries (26.5% YoY Growth) 1,281 Anterior Segment Reconstruction(1) (15.5% YoY Growth) Eidon Inmode 3D OCT Maestro 2 Corneal Transplants FFA Dry Eye Machine, Diagnostic OCT Machine (0.2% YoY Growth) Hyderabad Main Hospital, Telangana Chennai Main Hospital, Chennai Nikol, Gujarat Note: Specialized procedures performed during the six months ended Sep 30, 2026 7 (1) Includes Glued Intraocular Lens, Pinhole Pupilloplasty, Pre-Descemet’s Endothelial Keratoplasty Clinical Innovation | Pinh [Showing first 8,000 characters — download PDF for full document]